London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
When we see your Pigeon Pie stall Icecool, we'll all know. We'll know exactly what happened to all the missing pigeon.
Incidentally, AS will also have a stall there, his selling bags of a hundred 50p coins for Ā£40, while stocks last. A joint venture with TG. Sir-Mokin'!
Iām not telling you where I got my Pigeon from. Itās a secret š¤« same as the AGM location and time.
My pigeon must have been shot.
I am now on the lookout for another but more reliable pigeon, I am intrigued as to where icecool got his as it seems to have delivered an RNS with the AGM details.
You ask very pertinent questions Aldebaran, ones that we've all been dying to know the answers to for some time. Fortunately my notice of the AGM has just arrived this morning by Pigeon Post so I can relate details for anyone who hasn't received theirs yet or whose pigeon has been shot or otherwise lost.
The AGM will take place at The Mound, Old Sarum, Wilts at Sundown on the eve of the next Full Moon.
There won't be a presentation as such but, after the ritual trial of a TG in sackcloth and ashes by his peers, the remainder of the management team will be performing a quadrille to the tune of By The Light Of The Silvery Moon around the bound and gagged TG, who will then be taken off to the bonfire of Ā£50 notes and loan notes. Ignition around midnight.
Pitchforks and torches will be available from day traders if you haven't already purchased from reputable sauces. It'll be wild.
It's going to be massive, huge license deals announced. Can't wait, bigger than ASCO.
Started: gmcc, 15 Jun 2024 10:00
Last post: Wisheyedbortum, Today 15:08
Working from home. I note that the sales of mouse movers (mouse jigglers) is rocketing, which says all I need to know about those working from home!
Heās in your head Thorn, you sold out 18 months ago and still need to vent on a sunny Sunday morning. Have a day off
So many superlatives from the mouth of Dr Smith over the years.
LFTs, Affimers, PreCision.
They're all World Class and transformative.
Right up until they're not.
I remember at the time saying it was a huge over reaction.
(The largest demographic of illness and fatality were 80 plus already with co morbidities. (There was that terrible line in black humour when it turned out that the average age of death caused by Covid was 84 or something and was higher than the overall average age of death in the UK with the remark.... "If you want to live longer, get covid"
Given now the state of the NHS, education, and the general bankrupting of the country, work from home, acceleration of high street decline, inflation, closing down the economy has wrecked this economy for the foreseeable future.
Now you still get it and people just carry on, even though it can still be pretty unpleasant and debilitating.
There is little if any evidence that lockdown, mask wearing etc made any difference to the overall spread and time it spends in society.
The care home fiasco was due to a govt with no understanding with what it was dealing with or resource even if it had.
The world was caught unprepared for what in hindsight will be seen as a wakeup call to what a more deadly virus breakout, when it arrives will cause.
(Good job PL has me filtered as he still thinks we should have followed china's advice and had a100% lockdown.... No one in no one out, no movement. (quite how that would have worked never really got talked through. We were all to gleeful that we were going to be gazillionaires in a matter of days.)
Still NYCT did ok
I wish I was paid to post.
I'm a long term suffering investor looking at options avacta could turn this around.
I've seen nothing from affimersto boost the share price long term or dx.
Precision is the future for me. Get well into phase 2 and sell the company.
Don't all have to agree.
Started: 5RINGS, 15 Jun 2024 16:06
Last post: Wuckfit, 15 Jun 2024 19:05
Price: 40.25
The first one was allergic to the truth.
Busy living life to return to a CEO change. Why the change?
Started: LiveLongnProsper, 15 Jun 2024 15:04
Last post: LiveLongnProsper, 15 Jun 2024 15:04
GS Global Healthcare Conference June 10-13 2024. Wonder if this was where CC travelling to last weekend? A few āsnippetsā ā¦
Pfizer ā¦
https://s28.q4cdn.com/781576035/files/doc_events/2024/June/PFE-USQ_Transcript_2024-06-10.pdf
Very interested in ADCās (Seagen, others), also interested in CDK4 and bispecifics ā Affimer āspaceā then?
Merck ā¦
https://s21.q4cdn.com/488056881/files/doc_events/2024/Jun/11/mrk-usq_transcript_2024-06-11-3.pdf
āTissue-targetingā, āADC linker and payloadā. Looking beyond Keytruda.
BMS ā not from GS conf, but perhaps (?) worth a listen, particularly @ ~2:00 in ā¦
https://www.bms.com/media/media-library/scientific-media-resources/anti-cancer-advanced-modalities.html
Fascinating responses from Moderna, Pfizer, Gilead, Merck (Keytruda), Baxter, Sanofi, AbbVie, Lilly, Bicycle, Incyte, and others. All on āstandardisedā web pages, with a webcast link that requires registration. Only found Pfizer and Merck, so far, putting out a transcript.
If CC there, might explain the quiet week?
GLA
Last post: Toukankahmoon, 14 Jun 2024 18:18
stroking a warm ***** is very good for you.
back home for tea now after a swift schooner of pollys patternist.
ah well at least thereās no stock market to fret about over next two days though ny still open of course.
have good one everybody š
Don't be frightening the pussies now touk !!!
More worrying the bar isn't open until 3
Iām sat in local cat cafe having latte and cake. My local not open until 3pm. Thanks for caring
Your fingers must be on fire today !
Itās Friday time to go down the pub in a bit mate!
Calm down and chill
Started: Energyshares, 14 Jun 2024 08:17
Last post: Timster, 14 Jun 2024 18:04
Thank feck for the that disaster averted ....
Hallys baby nothing worry about here
Thereās only one way this is going
Thatās north
The noise clowns can just keep trying
But no one is listening
Closing sub 40 would be a very bad look on a technical level, hoping it holds that at least
18 months with better quality sounds even better. Poor fella's main ailment is getting sick of having to bother to get treatment when he's feeling fit as a fiddle
Also remember Mr 80% would have not experienced the debilitating side effects so as well as having his life extended it was done so in a much kinder way. Many people would rather 6 months without chemo and a better quality of life than 18 months longer with low quality.,
Started: Printerman62, 14 Jun 2024 10:54
Last post: RichPhil, 14 Jun 2024 11:29
Yes they have done wonders.
TCF put out a pretty good R&D Update yesterday, worth the watch imo
Yes....it's in the last couple of RNS's
Hi any idea when we might get some news that moves this share upwards please it just seems to be sinking?
TIA
Started: D-Geeman, 14 Jun 2024 08:53
Last post: Toukankahmoon, 14 Jun 2024 10:26
Iāve still got way too many ABDX shares
RE: Snippets13 Jun 2024 22:52
Last one - a post from Ivdeology about being a U.K. Responsible perso. Apparently they have 489 products registered with theMRHAand more joining weekly.
For AVCT investors on here, I noted that the Launch DX MD liked the post!
https://www.linkedin.com/posts/ivdeology-ltd_role-of-the-uk-responsible-person-and-the-activity-7207032517424525313-dbN1?utm_source=share&utm_medium=member_desktop
Started: Icecool, 13 Jun 2024 21:48
Last post: Icecool, 14 Jun 2024 08:46
They didnāt win it either was 4basebio. Carrier pigeon told me. Come on BV it was on the social media.. šš
Where did you see that? I wouldn't be surprised since we were up against Crispr AG which had the world's first approvals - the approval of approvals - for CRISPR technology and several nominations amongst the awards.
Truthfully I really couldnāt care less about awards, Iām just letting the BB know we didnāt win when we were shortlisted. The technology is proven, nothing in the current evidence suggests they wonāt see continued efficacy data as well in the 2w study. This is just a waiting game, in the meantime I will take full advantage of the current sentiment and continue loading up. The haters can hate all they want. š
Ice
Award winners arenāt always commercial successes. Iād rather Avacta be the latter. As you say, the platform mechanism is proven. But the rest is in the balance. Roll on the Summer and end of arm 2 and we should find out.
Competitions are subjective.
Good science is completely objective.
Rest assured if AVA600 is the real deal, and the trials have been done properly then investors should soon reap the rewards.
Started: LiveLongnProsper, 13 Jun 2024 19:26
Last post: Thompi, 14 Jun 2024 08:36
I wonder if there will be any board members from Diagnostics at the AGM. Or, if like the on the website they are consigned to the equivalent of a footnote. An embarrassing mistake airbrushed out of the equation.
No money left. We're doomed I tell ya we're doomed !!!
All staffed up. ā off we go
Recruitment freeze.
Is there a CFO vacancy showing?
Started: Energyshares, 13 Jun 2024 14:57
Last post: Benharper, 13 Jun 2024 22:08
18 months of your life, flat out finding or making up holes in an investment case even going to the extremes of making up logins to discuss this with. If youāre not up to something then you need mental health support. Canāt you see how weird it is, unless your up to something?
Not trolling.
Pointing out potential issues.
Choose to listen and you might not end up richer, but less poor.
Is that the same thing?
Or choose to be poorer, cross and wrong?
Your choice.
Science day was nearly 18 months ago you sad waste of space. 18 months trolling this share that your not invested in morning, noon and night. Now if you think selling at science day and then wasting 18 months of your life doing that is a win, then there really is no hoping you
P.S. Glad to see you still respond to 'Eggy'!! LoL
Poor Eggy, No wonder he has a persecution complex eh? PMSL
Started: NFTs, 12 Jun 2024 09:51
Last post: Icecool, 13 Jun 2024 16:36
richar more a hypocrite than a de-ramper tbh. tells everyone to ignore, yet decides to join in anyways to stir the **** up. šš
Hi richar, when I was... brilliant. I know you're a fan, keep me on your list.
Yes PL75 I have followed your posts a long time i can remember when you was a deramper.
Jelly much š¤£š lol
Sorry PL - young 'retired' lad!!
Started: SNewby, 10 Jun 2024 09:41
Last post: Watching2, 13 Jun 2024 14:38
The wise are buying and the fools are selling !
Impossibly holding above 40. What's with this floor?
That is inconveniently embarrassing.
You also said, which you may have forgotten:
"We should all be happy that Avacta are out there making a real difference for cancer patients. It isn't about the share price, it's about being part of a great movement. Not sure why we've lost sight of this since dropping"
Spot who just sold . Lol
Started: Apre, 13 Jun 2024 11:32
Last post: Apre, 13 Jun 2024 11:32
. . . . Eggy. A constant stream of nasty, spiteful cynicism and vitriol. As disgraceful as it is sad.
You are clearly lost.
Started: gmcc, 13 May 2024 07:59
Last post: gmcc, 13 Jun 2024 11:00
LD wide range of products .
https://biosystems.global/service/clinical-analysis/biochemistry-systems/analysers/a15s
https://www.linkedin.com/feed/update/urn:li:activity:7206951195674849280/
Launch Diagnostics Limited
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,756 followers1,756 followers
19m ā¢ 19 minutes ago
Enhance your laboratory efficiency with the BioSystems A15s, specifically designed for faecal calprotectin and faecal immunochemical testing (FIT). The A15s boasts a straightforward sample extraction process, no need for complex steps or centrifugation.
The A15s supports continuous loading to keep your workflow smooth and uninterrupted. With a throughput of 75 tests per hour you can handle samples efficiently and effortlessly.
The A15s is engineered to deliver high-quality performance, ensuring confidence in test outcomes. Choose the BioSystems A15s to elevate your laboratory capabilities.
Minimise your efforts, Maximise your results.
For further information contact your local Launch representative or go to our website.
www.LaunchDiagnostics.com
#IBS
#Calprotectin
Fyi "Launch Diagnostics LimitedLaunch Diagnostics Limited
1,747 followers1,747 followers
4h ā¢ 4 hours ago
https://bsmm.org/BSMM_2024/annual-bsmm-conference-2024/
Today we are attending the 58th Annual Conference for the British Society for Medical Mycology in Cardiff!
Looking forward to seeing our mycology colleagues as well as all the latest updates.
If youāre attending please stop by our stand to say hello!
#mycology #diagnostics #NHS #mycologists #biomedicalscience #researchscience #innovation #patientcare"
--------------
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,747 followers1,747 followers
4h ā¢ 4 hours ago
https://www.launchdiagnostics.com/product/virionserion-immunocontrols/
Third Party Serology controls may be used for day-to-day monitoring of assay performance and validations where sourcing clinical specimens is difficult, whilst simultaneously meeting regulatory requirements and increasing confidence in diagnostic results.
The Immunocontrol range from Virion\Serion is compatible with a wide range of assays and technologies, and is lyophilised for convenience and stability.
For more information and a list of our control repertoire, please visit our website.
Alternatively, email us at enquires@aunchdiagnostics.com, or contact your local Territory Manager.
https://lnkd.in/gDg-4cti
hashtag#virionserion hashtag#launchdiagnostics hashtag#infectiousdiseases hashtag#thirdpartyqc
Virion\Serion Immunocontrols - Launch Diagnostics
launchdiagnostics.com
Not forgetting Coris global AMR reach
https://www.corisbio.com/presentation/company-profile
"Anti-Microbial Resistance concern pushed Coris BioConcept to develop a range of assays (RESIST) for rapid detection of antibiotic resistance mechanisms. Aside of this range, another innovative approach for 3GC detection was recently launched with a front line test: BL-RED.
This R&D expertise is ideally suited for āon demandā production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConceptās products fulfil the CE marking requirements with an ISO 13485 certification and they are used in over 60 countries all over the world."
Good Morning - LD good at promoting manufactuer products -- Not sure on UK market AMR revenue size but seems to be an area of concern ,
https://www.gov.uk/guidance/antimicrobial-resistance-amr
https://www.launchdiagnostics.com/product/antimicrobial-susceptibility-testing-solutions/
"The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period
-------------
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,730 followers1,730 followers
1d ā¢ 1 day ago
Launch Diagnostics are the UKās exclusive distributor of Liofilchemās AMR portfolio, including their comprehensive range of antibiotic discs for detection of microbial resistance mechanisms.
Antimicrobial resistance (AMR) is one of the biggest health threats we face. Launch Diagnostics are committed to supporting healthcare professionals in the fight against AMR, through the supply of high-quality resistance testing tools, which help both in patient management and in contributing to global AMR surveillance efforts.
Liofilchemās disc range is designed to detect various resistance mechanisms including:
ā¢ Extended-Spectrum Beta-Lactamases (ESBLs)
ā¢ AmpC Beta-Lactamases (AmpC)
ā¢ Klebsiella pneumoniae Carbapenemases (KPCs)
ā¢ Metallo-Beta-Lactamases (MBLs)
ā¢ OXA-48-Like Carbapenemases (OXA-48)
For more information visit the website, email us at enquiries@launchdiagnostics.com, or speak with your local territory manager.
https://lnkd.in/eDnZ-G-Y
hashtag#antimicrobialresistance hashtag#WHO hashtag#diagnostics hashtag#fightagainstAMR hashtag#innovation hashtag#collaboration hashtag#NHS hashtag#patientcare hashtag#biomedicalscience
More good news
https://www.mikrogen.de/en/
"
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,721 followers1,721 followers
6h ā¢ 6 hours ago
Launch Diagnostics partner with Mikrogen, distributing the Amplicube range of PCR assays for infectious diseases diagnostics and AMR testing.
With a broad range of assays available, and a common thermal protocol across the range, Amplicube kits offer exceptional performance and quality. Whether it's in infectious diseases testing, research, or beyond, Mikrogen PCR kits deliver reliable results, empowering scientists and clinicians with the information needed for patient management.
Stay ahead in your field with Mikrogen Amplicube PCR kits! For further information visit the Launch Diagnostics website, email us at enquiries@launchdiagnostics.com or speak to your local territory manager."
Started: LiverpoolBay, 12 Jun 2024 19:05
Last post: LiverpoolBay, 12 Jun 2024 19:05
A couple of LinkedIn profile changes I noticed today.
Fiona McLaughlin's position as Chief Scientific Officer appears to have ended this month; and
James Heseltine, previously Group Financial Controller, is Deputy CFO from this month.
Started: Hurst10, 12 Jun 2024 17:42
Last post: Thinkin, 12 Jun 2024 18:17
BMS chief Boerner says company is still hungry for deals after spending more than $20B on M&A last year.
As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibbāhot off a series of rapid-fire acquisitions in 2023āsays it still has dealmaking cash to deploy if the right target comes along.
BMS can continue to indulge its business development appetite thanks to its strong balance sheet, CEO Christopher Boerner told investors this week at Goldman Sachsā 2024 Global Healthcare Conference.
āWeāre going to be disciplined, as I said, and pay down the debt we accrued in doing the deals last year,ā the CEO noted. āBut with that in mind, as we look at opportunities, weāre focused on the therapeutic areas weāre in.ā
BMS charted a number of high-profile buyouts last year, starting with its $5.8 billion deal for KRAS inhibitor specialist Mirati Therapeutics in October.
Then, shortly before Christmas, the company threw down $14 billion more for Karuna Therapeutics and its promising schizophrenia candidate KarXT. Just before the end of the year, BMS floated another $4.1 billion for radiopharmaceutical-focused RayzeBio.
Started: Waggy42, 4 Mar 2024 22:38
Last post: D-Geeman, 12 Jun 2024 14:32
DTW; wasn't there was a thread about you? :-)
There is no CSO ...yet. Hopefully won't be AS in future. Zero credibility.
Avacta must hire smart people or they won't grt anything done. CSO can't do diddly.
NYsize must've got the spreadsheets mixed up again.
Waggy - you're posting history on this stock is something to behold...! Are you bipolar?
I'm usually getting called a troll etc from the goons on this board, but honestly, are you okay fella?
One minute this is the best investment on AIM, the next we're about to enter liquidation.
You're either mentally ill, or have an underhand agenda at play here....
Started: Energyshares, 12 Jun 2024 10:44
Last post: CTSFO, 12 Jun 2024 13:26
Echoing Wyn, best wishes to your daughter, hope the physio is helping. š
Posting en-route to the pool. Thanks wyn.
This example of good news just popped up on my phone. Maybe my luck is changing;
Today we have announced that the FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis.
$TLSA #MultipleS
jc, made me laugh too. itās actually hydrotherapy for daughter.
wyn, i noticed you bought bab**** engineering a short while ago. jc inspired me to check my watchlist and i see itās +20.36 since then. well done.
jc, what have you bought recently thatās done well? i might ask you for tips if the answer is a good one.
That is the million dollar question D.
It really depends on what the buyer want/expects.
If AVCT release data- rich, good news and the SP jumps to...say.. 100p? then 2 things can happen it can go up further or fall. (An unexpected RNS would suggest just buy in asap and hang on for dear life. Normally however, there are some nibbles in the SP that might get you to buy prior to the unexpected news.)
Its impossible to know which one will happen For me, as you know I would use the RSI to help with that decision, but that just helps the odds of being right, its no guarantee.
If you think, that's it, the course is set and I will hold now to see it through and its 2 years at least , then a potential retrace to 80p or whatever, becomes largely irrelevant.
For my part, I can be a LTH and trade it at the same time. Thats not an accident, I am trying my best to have the best of both worlds, but its not for everyone.
Ultimately, whatever "system" you use, there should be a plan. Why am I buying, right now, at this price? Will it go lower? maybe but I don't want to risk missing out? You have to examine your motivations to see if they are rational or emotional.
Then once you have bought, how long do you expect to hold them for, and what price are you aiming for when to sell?
And if you get it wrong (as we all do), then when do you crystalise the loss?
Honestly and sincerely, I don't know how anyone can buy a stock for whatever reason and not have these questions answered in their head.
So I think it is wise to consider the what if's, as if it does occur you can act accordingly.
What makes this harder (AVCT) is that it is a loss making company and therefore large swings will always accompany such entities. The individual has to decide what they want from it given its high risk.
The plan may, as events occur, need adjusting but most shouldn't. (For me TA is more mechanical and removes a lot of the emotion out of these parameters, but each to his own.)
What I don't get is to buy a stock and have never considered answering any of those questions.
Like everything there is no right and wrong when trying to predict the future......
The fact is this buying high risk small cap companies is almost always going to result in capital depreciation for the individual.
Getting rich slowly is actually pretty easy if you can save a few thou per annum regularly. The irony is that youth wants to get rich quick and when you realise the solution you are too old!! :0))
(Best wishes to your girl xx)
Off to see a psychiatrist more like D-Geeman, asking Winnie for share advice, made my day that. š š
Started: HereKittyKitty, 12 Jun 2024 11:40
Last post: WeAreGroot, 12 Jun 2024 12:12
Then do some research on the opportunity? check out the last time Avacta was shorted and by how much and review what effect it had on the sp? Ask yourself if the fundamental opportunity as represented by the science and trial results is strong enough to satiate your risk appetite?
Better that than asking the board if they know when a short will be closed? if you need that sort of info maybe call Mystic Meg?
I do as they have bet Ā£1.4m on downside and that's what an investing chat board is here for
Who cares?
So they took out the following positions on their 0.81% short:
16 Apr 0.50% @ 51.5
24 Apr 0.10% @ 44.5
9 May 0.10% @ 44.7
28 May 0.11% @ 44.1
When will they cash out?
50-day moving average 45.99
200-day moving average 94.00
Seems a risky short?
Last post: martnotsosmart, 12 Jun 2024 09:47
LSE can I have my capital letters back please!
Almost.yes these great treatments are sadly a sig way off volume application. The very need to personalise is a barrier.
Volume drug application are here for some time . Enhancements such as 6000 are interesting to BP.
CC signalled clearly that talks are keeping the new CD busy.
Strange markets not seen this clearly?
Shorter GSM playing games no doubt .
GLA
weāre all waiting for the next bit of advice from our resident scarecrow!
ādo you actually research the other promising cancer treatments?ā
āit isnāt research unless it considers the wider picture.ā
ācustomised anti cancer vaccines will blow chemotherapy out the water in a few years time.ā
seriously! these novel immunological approaches to treatment and prevention are often unique to the individual patient. there are so many variables from patient to patient that it is almost certain that this approach to treatment will join, not replace, the current therapeutic ****nal.
in fact if you do the basic research required to understand cancer vaccines you would soon discover that almost every review offers a similar viewpoint going forward; much of the focus in the development of cancer vaccines will shift towards the use of vaccines as combinatorial treatments with eg immune checkpoint inhibitors and/or other approaches such as chemo- and radiotherapy.
āit is becoming increasingly more apparent that, as part of the design of vaccine regimens, combination therapy might be a better treatment option compared to monotherapy for durable clinical responses. combination regimens currently being explored include differing immunotherapeutic approaches including vaccines combined with conventional chemotherapy and radiation therapy.ā
āclinical responses generated by cancer vaccines are heavily governed by indication, antigen selection, patientāspecific factors, vaccine type, and combination therapies. our evaluation (2023) of ongoing clinical trials indicates that adept attention to all these factors will be a major determinant of the future success of cancer vaccines. because many cancer vaccine trials often take years to proceed from each clinical phase to the next, the current analysis does not yet reflect many promising preclinical interventions, including novel adjuvants and drug delivery carriers. although clinical results have been disappointing to date, the latest data indicate that there may be a more permanent niche for vaccines in the expanding repertoire of therapeutic interventions against cancer.ā
cancer vaccines will simply be another tool in the box alongside chemotherapy, radiotherapy and other immunotherapy approaches at least for the next decade or so.
https://www.mdpi.com/2076-393x/11/12/1783
https://www.mdpi.com/2076-393x/6/3/52
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10771564/
if you are going to take your lead from sunday press articles the least you can do is check out the relevance and filter out the hype!
Day
Started: gmcc, 12 Jun 2024 09:44
Last post: gmcc, 12 Jun 2024 09:44
Good Morning . Courtesy of twitter .
by Emily Govan 11 June 2024
https://www.imperial.ac.uk/news/254013/centre-structural-biology-open-day-2024/
"There was a stellar line-up including Senior Director of Astex Pamela Williams, UK Head of Structural and Biophysical Sciences at GSK, Chun-wa Chung, Principal Scientist Manuel Pinto at Avacta, and Oliver Sims from venture capitalist firm Octopus Ventures."
Linkedin " Manuel Pinto Principal Scientist, Therapeutics, at Avacta Life Sciences
April 2023, I have joined Avacta Life Sciences as Principal Scientist in the Protein Team of the Therapeutics Division, working on the Affimer biotherapeutics platform."
Manuel Pinto involved with AffimerĀ® biotherapeutics: Next generation platform for cancer therapies
https://avacta.com/wp-content/uploads/2023/11/PEGS-Europe-2023-poster.pdf
--------
Lot going on at Avacta . Do believe eventually true value of company asset IP will prevail . Personally be great to see Avacta science being used in patient clinical treatments/diagnosis . Not that bothered how that is achieved . No issue waiting for investor/shareholder return , prefer to increase Ā£stake and hold long term .( albeit look forward to being back in paper profit )
-------------
" Core holdings are the central investments of a long-term portfolio - Typically, long-term investing means five years or more, but thereās no firm definition. "
-------------------
---- apparently some here think,bad mouthing the company is OK & remind us on a daily basis - in/out trading of numerous stocks in the hope of getting a 10-15% profit to protect capital is a better approach - seem fixated with the SP & number of shares you might get at a lower price , is a better way , good luck with that .
Started: oldtrader2, 12 Jun 2024 09:08
Last post: oldtrader2, 12 Jun 2024 09:08
Stifel the sacked broker been on offer since announcement !!
Started: Energyshares, 11 Jun 2024 15:23
Last post: B2HS2L, 11 Jun 2024 21:48
Energyshares - re your original post:
"Could Avacta offer Lilly extra exclusive licenses to the pre|CISION technology for use in a few more radiopharmaceutical prodrugs.
Under the terms of the Point agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT."
If Avacta were to offer Lilly one extra exclusive licence for use in one more radiopharmaceutical prodrug, at an attractive price, might the announcement of that deal, show other interested parties that Lilly were making use and benefitting further from their purchase of Point Bio.
This could encourage others to the negotiating table and 'get this party started'
in terms of signing deals targeting therapies to tumours and avoiding systemic toxicities.
Just a thought.
Energyshares...I might have not made my question very clear. Lilly have just agreed a lucrative partnership deal with Aktis. The Point/Avacta deal is a less lucrative licence deal. Would Lilly be likely to want to turn the Licence deal they've just inherited through the Point purchase into a Partnership deal to incorporate some of the new up snd coming PreCision products. What we don't know is at what stage they are at with the CanSEEK enabled products...or do we? I can't find any Lilly updates.
WaG
My money on Novartis if indeed anyone
Or Lilly are simply doing there own FAP targeting molecule (with the help of Tufts - who should be familiar) ..?
https://jnm.snmjournals.org/content/early/2023/11/30/jnumed.123.266345
Actually think it highlights the value of pre|CISIONā¢ even more so, if maybe not Lilly at the 'front of the pack'?
Other BP's are available and 'Big Pharma' means 'Big' resources.
GLA
Bella,
Canseek IP belongs to Avacta Point did think they had a licence from Tufts but if I remember right Avacta corrected them it was there IP and tufts agreed.
Started: Timster, 11 Jun 2024 17:13
Last post: Icecool, 11 Jun 2024 20:44
Pharma, will do š¤©, currently living the dream having fun everyday. Whatās not to be positive about regarding Avacta, fully funded moving into H2 milestones.
Fair enough.. just donāt write up anything to tell others to ignore!
Have fun. I certainly appreciate your posts Icecool. Keep up the positive!
It isnāt research unless it considers the wider picture.
Itās like putting your money on your favourite at the Cheltenham Cup just because they are on top form without doing any research on the other horses and riders.
Iām not moaning though, saying ignore them, everyone slates the numpties. You, me, PL75, everyone does it, ok maybe not Bella. However itās a BB, ignoring is so boring š„± came to that conclusion when i filtered them previously.
Your guys just canāt seem to ignore them. Hypocrites yourselves!